Highlights in inflammatory bowel disease - From bench to bedside

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 7, 2012, Pages 1229-1235

  Engel, Matthias A ^a   Khalil, Mohammad ^a   Neurath, Markus F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cytokines; Gene therapy; Neuro immune interaction

Indexed keywords

ANTIBIOTIC AGENT; CALCITONIN GENE RELATED PEPTIDE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; COMPLEMENTARY RNA; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 18; INTERLEUKIN 4 ANTIBODY; NEUROKININ 1 RECEPTOR; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 10; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VANILLOID RECEPTOR 1;

ADAPTIVE IMMUNITY; ANTISENSE THERAPY; CD8+ T LYMPHOCYTE; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; INNATE IMMUNITY; MACROPHAGE; MICROFLORA; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; ULCERATIVE COLITIS;

ANIMALS; CYTOKINES; GENETIC THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; MICE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84867798365     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0831     Document Type: Review

References (68)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
2. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
5. Laukoetter MG, Mennigen R, Hannig CM, Osada N, Rijcken E, Vowinkel T, et al. Intestinal cancer risk in Crohn's disease: a metaanalysis. J Gastrointest Surg 2011;15:576-83.
6. Pugazhendhi S, Amte A, Balamurugan R, Subramanian V, Ramakrishna BS. Common NOD2 mutations are absent in patients with Crohn's disease in India. Indian J Gastroenterol 2008;27:201-3.
7. Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 2006;12:3668-72.
8. Zhernakova A, Van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009;10:43-55.
9. Budarf ML, Labbé C, David G, Rioux JD. GWA studies: rewriting the story of IBD. Trends Genet 2009;25:137-46.
10. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008;40:1319-23.
11. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008;40:713-5.
12. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604.
13. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-2.
14. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-62.
15. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 asso ciated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
16. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, et al. Loss of the autophagy protein Atg16L1 enhances endotoxininduced IL-1beta production. Nature 2008;456:264-8.
17. Sachar DB. Studying inflammatory bowel disease in the global laboratory. J Gastrointestin Liver Dis 2009;18:407-9.
18. Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009;360:1696-8.
19. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005;307:1920-5.
20. Neutra MR, Mantis NJ, Kraehenbuhl JP. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol 2001;2:1004-9.
21. Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005;115:66-75.
22. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69.
23. Melis D, Parenti G, Della Casa R, Sibilio M, Berni Canani R, Terrin G, et al. Crohn's-like ileo-colitis in patients affected by glycogen storage disease Ib: two years' follow-up of patients with a wide spectrum of gastrointestinal signs. Acta Paediatr 2003;92:1415-21.
24. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995;270:1203-7.
25. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 2009;27:313-38.
26. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006;312:1355-9.
27. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-4.
28. Peterson DA, Frank DN, Pace NR, Gordon JI. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 2008;3:417-27.
29. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313-23.
30. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 2011;478:250-4.
31. Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA 2008;105:20858-63.
32. Umesaki Y, Setoyama H, Matsumoto S, Okada Y. Expansion of alpha beta T-cell receptor-bearing intestinal intraepithelial lymphocytes after microbial colonization in germ-free mice and its independence from thymus. Immunology 1993;79:32-7.
33. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-5.
34. Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008;4:337-49.
35. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008;455:1109-13.
36. Mach T. Clinical usefulness of probiotics in inflammatory bowel diseases. J Physiol Pharmacol 2006;57:23-33.
37. Cossart P, Sansonetti PJ. Bacterial invasion: the paradigms of enteroinvasive pathogens. Science 2004;304:242-8.
38. Bar-On L, Zigmond E, Jung S. Management of gut inflammation through the manipulation of intestinal dendritic cells and macrophages? Semin Immunol 2011;23:58-64.
39. Hontecillas R, Horne WT, Climent M, Guri AJ, Evans C, Zhang Y, et al. Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal Immunol 2011;4:304-13.
40. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-98.
41. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998;22:382-9.
42. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
43. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1756-67.
44. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79.
45. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-41.
46. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159:6276-82.
47. Westbrook CA, Chmura SJ, Arenas RB, Kim SY, Otto G. Human APC gene expression in rodent colonic epithelium in vivo using liposomal gene delivery. Hum Mol Genet 1994;3:2005-10.
48. Li M, Lonial H, Citarella R, Lindh D, Colina L, Kramer R. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Ther 1996;3:221-9.
49. During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med 1998;4:1131-5.
50. Wirtz S, Galle PR, Neurath MF. Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure. Gut 1999;44:800-7.
51. Foreman PK, Wainwright MJ, Alicke B, Kovesdi I, Wickham TJ, Smith JG, et al. Adenovirus-mediated transduction of intestinal cells in vivo. Hum Gene Ther 1998;9:1313-21.
52. Kitani A, Fuss IJ, Nakamura K, Schwartz OM, Usui T, Strober W. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med 2000;192:41-52.
53. Palffy R, Gardlik R, Behuliak M, Jani P, Balakova D, Kadasi L, et al. Salmonella-mediated gene therapy in experimental colitis in mice. Exp Biol Med (Maywood) 2011;236:177-83.
54. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319:627-30.
55. Engel MA, Becker C, Reeh PW, Neurath MF. Role of sensory neurons in colitis - increasing evidence for a neuro-immune link in the gut. Inflamm Bowel Dis 2011;17:1030-3.
56. Engel MA, Leffler A, Niedermirtl F, Babes A, Zimmermann K, Filipovic' MR, et al. TRPA1 and substance P mediate colitis in mice. Gastroenterology 2011;141:1346-58.
57. Di Sebastiano P, Grossi L, Di Mola FF, Angelucci D, Friess H, Marzio L, et al. SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis. Dig Dis Sci 1999;44:439-44.
58. Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, McClung J, et al. NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol 2000;279:1298-306.
59. Engel MA, Khalil M, Siklosi N, Mueller-Tribbensee SM, Neuhuber WL, Neurath MF, et al. Opposite effects of substance P and calcitonin gene-related peptide in oxazolone colitis. Dig Liver Dis 2012;44:24-9.
60. Evangelista S, Tramontana M. Involvement of calcitonin gene-related peptide in rat experimental colitis. J Physiol Paris 1993;87:277-80.
61. Clifton MS, Hoy JJ, Chang J, Idumalla PS, Fakhruddin H, Grady EF, et al. Role of calcitonin receptor-like receptor in colonic motility and inflammation. Am J Physiol Gastrointest Liver Physiol 2007;293:36-44.
62. Talme T, Liu Z, Sundqvist KG. The neuropeptide calcitonin generelated peptide (CGRP) stimulates T cell migration into collagen matrices. J Neuroimmunol 2008;196:60-6.
63. Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol 2008;8:460-71.
64. Fujino K, Takami Y, De La Fuente SG, Ludwig KA, Mantyh CR. Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis. J Gastrointest Surg 2004;8:842-7.
65. Kihara N, De La Fuente SG, Fujino K, Takahashi T, Pappas TN, Mantyh CR. Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut 2003;52:713-9.
66. Szitter I, Pozsgai G, Sandor K, Elekes K, Kemeny A, Perkecz A, et al. The role of transient receptor potential vanilloid 1 (TRPV1) receptors in dextran sulfate-induced colitis in mice. J Mol Neurosci 2010;42:80-8.
67. Massa F, Sibaev A, Marsicano G, Blaudzun H, Storr M, Lutz B. Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis. J Mol Med 2006;84:142-6.
68. Caceres AI, Brackmann M, Elia MD, Bessac BF, Del Camino D, D'Amours M, et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc Natl Acad Sci USA 2009;106:9099-104.